Company Announces Partnership with Rwanda Development Board to Make Affordable Treatments for Patients in AfricaSAN FRANCISCO and KIGALI, R ...

Brain oedema after major ischaemic infarction is a life-threatening complication for which no preventive therapy exists. Decompressive hemicraniectomy can be lifesaving and improve functional outcomes ...

Emmecell has published positive topline outcomes from a Phase I trial of EO2002, its nonsurgical cell therapy candidate for ...

Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...

The study confirmed that Afqlir has equivalent efficacy and comparable safety to its reference medicine, Eylea.

(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.

"It is announced that the instrumental examinations to which è athlete Niccolò De Vico underwent showed an oedema of bone ...

The NHS is warning people to be vigilant for a potentially fatal symptom that could indicate heart failure. The health body ...

There is no cure for heart failure and it typically gets worse over time with around half of patients dying within five years ...

On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...